Steve Pakola Sells 2,161 Shares of REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 2,161 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $13.64, for a total transaction of $29,476.04. Following the sale, the insider directly owned 213,009 shares in the company, valued at $2,905,442.76. The trade was a 1.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Steve Pakola also recently made the following trade(s):

• On Monday, June 29th, Steve Pakola sold 19,608 shares of REGENXBIO stock. The stock was sold at an average price of $11.04, for a total transaction of $216,472.32.
• On Wednesday, July 1st, Steve Pakola sold 36,725 shares of REGENXBIO stock. The shares were sold at an average price of $12.86, for a total value of $472,283.50.
• On Monday, May 11th, Steve Pakola sold 15,309 shares of REGENXBIO stock. The shares were sold at an average price of $11.02, for a total transaction of $168,705.18.

REGENXBIO Stock Up 1.3%

Shares of NASDAQ RGNX opened at $15.02 on Wednesday. The firm has a market cap of $776.53 million, a price-to-earnings ratio of -2.68 and a beta of 0.90. The company’s 50-day simple moving average is $8.53 and its 200-day simple moving average is $9.92. REGENXBIO Inc. has a 52-week low of $5.45 and a 52-week high of $16.19.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($1.72) EPS for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.36). REGENXBIO had a negative return on equity of 232.50% and a negative net margin of 330.23%.The company had revenue of $6.39 million for the quarter, compared to analysts’ expectations of $25.84 million. Equities research analysts anticipate that REGENXBIO Inc. will post -3.69 EPS for the current fiscal year.

Institutional Trading of REGENXBIO

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC raised its holdings in REGENXBIO by 2,247.7% during the first quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company’s stock worth $4,437,000 after purchasing an additional 594,161 shares in the last quarter. Jane Street Group LLC boosted its position in shares of REGENXBIO by 151.1% during the 1st quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company’s stock worth $2,961,000 after purchasing an additional 249,156 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of REGENXBIO during the 2nd quarter worth $239,000. American Century Companies Inc. increased its holdings in shares of REGENXBIO by 8.4% in the 2nd quarter. American Century Companies Inc. now owns 110,066 shares of the biotechnology company’s stock valued at $904,000 after purchasing an additional 8,487 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new position in shares of REGENXBIO in the 2nd quarter valued at about $87,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RGNX has been the subject of several recent research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of REGENXBIO in a research report on Monday, June 8th. Morgan Stanley set a $16.00 price objective on REGENXBIO in a research note on Friday, May 15th. HC Wainwright reiterated a “buy” rating and issued a $26.00 target price on shares of REGENXBIO in a report on Wednesday, July 1st. Robert W. Baird boosted their target price on REGENXBIO from $27.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, June 22nd. Finally, Barclays cut their price target on REGENXBIO from $37.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, May 15th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.82.

About REGENXBIO

REGENXBIO Inc is a clinical?stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno?associated virus) platform. The company engineers next?generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age?related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.